argenx   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Breda Netherlands (2009)

Organization Overview

First Clinical Trial
2013
NCT01813539
First Marketed Drug
2021
efgartigimod
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

argenx | ARGENX BV | argenx BVBA | arGEN-X BVBA

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Myelomonocytic, Chronic (Phase 2)

Leukemia, Myelomonocytic, Juvenile (Phase 2)

Muscle Weakness (Phase 3)

Myasthenia Gravis (Phase 3)

Myelodysplastic Syndromes (Phase 2)

Nasopharyngeal Carcinoma (Phase 1)

Neoplasms (Phase 1)

Paresis (Phase 3)

Pemphigus (Phase 3)

Polyneuropathies (Phase 2)

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (Phase 2)

Preleukemia (Phase 2)

Purpura, Thrombocytopenic, Idiopathic (Phase 3)

Syndrome (Phase 2)

Thrombocytopenia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 35
  • # of Trial APIs: 9